Congress mandates pharmacy access to birth control, creates private right to sue

What it does

This bill requires pharmacies to dispense FDA-approved contraceptives and related medications without delay, without intimidation or deception, and without refusal based on personal beliefs. Pharmacies must offer referrals or expedited ordering if items are out of stock. The bill creates civil penalties (up to $1,000/day, capped at $100,000 per case) and a private right of action for customers denied service, while carving out exceptions for lack of valid prescription, inability to pay, and professional clinical judgment.

Why we flagged it

The bill's operative mechanism is a duty imposed on pharmacies to dispense contraceptives without delay or discrimination, backed by civil penalties and private litigation rights. It is a public-health access mandate, not a subsidy or deregulation.

What the text implies

• The private right of action creates potential for high-volume litigation against pharmacies; damages are uncapped except for civil penalties, creating asymmetric litigation risk.
• The 'professional clinical judgment' exception is undefined and may become a litigation flashpoint—pharmacists could claim clinical grounds for refusal, forcing courts to define the boundary.
• The bill does not address insurance coverage or cost-sharing; it mandates provision but not affordability, leaving cost barriers intact for uninsured or underinsured customers.
• State law preemption clause preserves stronger state protections but creates a patchwork; pharmacies in low-protection states face higher compliance risk.
• The 31-day effective date (before guidance is issued) may create immediate compliance uncertainty for pharmacies on what 'without delay' and 'professional clinical judgment' mean in practice.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain enforceable access to contraception without delay or discrimination, with a private right of action to sue for denial of service. The bill removes a documented barrier to healthcare (pharmacist refusals) and protects reproductive autonomy. Exceptions for valid prescriptions, payment, and clinical judgment preserve legitimate pharmacy operations.

Who stands to gain

• pharmaceutical manufacturers (increased contraceptive sales volume)
• generic drug makers (OTC and prescription contraceptive producers)

Named in the bill

FDA, Department of Health and Human Services, State pharmacy boards, Pharmacies (retail), Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ), Religious Freedom Restoration Act, Patient Protection and Affordable Care Act, Title VII Civil Rights Act

Where it stands

52 cosponsors: 52 Democrats.

• Jun 23, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jun 23, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $43,451 in lobbying spend. A filing names 48 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Robin Kelly, the sponsor, reported $539,150 in PAC receipts in the 2026 cycle.

• Power to Decide — $33,451 on 2 filings
• National Council of Jewish Women — $10,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.